GlassScriptPhysician profile
Mia Moran
NPI 1619735131
$3,357.99
in general payments reported to CMS, 2019-2025
20 companies · $1,749 in 2025
The $1,749 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,609 · 2025: $1,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,231 · Travel and Lodging: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,230.97 |
| Travel and Lodging | $1,127.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,295.10 | 2024 | Axonics |
| Bayer Healthcare Pharmaceuticals INC. | $297.42 | 2025 | |
| Accord Healthcare, INC. | $217.98 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $216.75 | 2024-2025 | Gemtesa |
| Telix Pharmaceuticals | $192.40 | 2024-2025 | Illuccix |
| Coloplast Corp | $179.01 | 2025 | |
| Urogen Pharma, INC. | $154.25 | 2025 | |
| Antares Pharma, INC. | $135.69 | 2024-2025 | Xyosted |
| Janssen Biotech, INC. | $134.81 | 2025 | Rybrevant, Carvykti, Erleada |
| 180 Medical, INC. | $103.32 | 2024-2025 | Gentlecath |
| Endo USA, INC. | $92.38 | 2025 | Xiaflex, Aveed |
| Ferring Pharmaceuticals INC. | $73.84 | 2025 | Adstiladrin |
| Blue Earth Diagnostics | $61.00 | 2025 | Posluma |
| Immunitybio, INC. | $46.41 | 2025 | |
| Myriad Genetic Laboratories, INC. | $39.32 | 2024-2025 | Prolaris |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $31.84 | 2025 | |
| Teleflex LLC | $28.33 | 2025 | Barrigel |
| Cycle Pharmaceuticals INC | $24.50 | 2025 | Venxxiva |
| Takeda Pharmaceuticals U.S.A., INC. | $20.12 | 2025 | Entyvio |
| Boston Scientific Corporation | $13.52 | 2024 | Lithovue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mia Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.